Will Monopar Therapeutics stock regain momentum as buyers support the ongoing rally?

Traders Union
All News
Financial News
Monopar Therapeutics up 3.21% today

Highlights

MNPR/USD demonstrates a broadly bullish trend, trading above key short-, medium-, and long-term technical levels.
Momentum indicators show continued buying strength but multiple oscillators are in overbought territory, suggesting near-term caution.
Price is projected to consolidate in the $95.81–$117.49 range, with a 73% probability of upward movement and $104.98 as immediate support.

Uptrend support as technical signals hint at exhaustion

On the H1 chart, MNPR is trading above the MA-20 at $104.09 and the MA-50 at $100.93, and remains comfortably above the long-term MA-200 at $69.69. The Ichimoku Kijun acts as immediate support at $104.98. The Moving Average Convergence Divergence (MACD) shows a buy condition with no clear directional signal from the Average Directional Index (ADX). The Relative Strength Index (RSI) is at 60.7, supporting buying momentum, though both Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power are in overbought zones. The Awesome Oscillator displays confirmation of the current uptrend, but oscillator divergence suggests caution as some indicators point toward exhaustion from recent buyer activity.

Range-bound outlook as breakout risk remains elevated

Looking ahead, MNPR is likely to consolidate within a band of $95.81 to $117.49 over the coming days, reflecting typical volatility for the asset. There is a 73% probability that price continues higher and only a 27% chance of a downward move. The baseline scenario involves sideways trading between immediate support at $104.98 and upper resistance. A clear break above resistance may open the path to the top of the forecast range, while a decisive move below support could invite additional short-term selling pressure.

Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics trading with strong technical momentum, though without any supporting corporate news. He notes the price remains above all key moving averages, with momentum indicators flashing overbought signals and some signs of buyer exhaustion. Kharitonov remains cautious about the sustainability of the move given the absence of news catalysts. "Until a clear breakout above $117.49 or a breakdown below $104.98, I prefer to stay defensive and wait for a stronger confirmation from price action."

Earlier, analysts noted that Monopar Therapeutics was experiencing strong bullish momentum but cautioned that downside risk had emerged following an analyst downgrade. The current technical setup suggests traders should monitor for a decisive move above resistance to confirm renewed direction or remain cautious of potential short-term weakness should immediate support fail.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.